Cargando…

Correction: CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies

Detalles Bibliográficos
Autor principal:	Bullock, Timothy N. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243120/ https://www.ncbi.nlm.nih.gov/pubmed/35655097 http://dx.doi.org/10.1038/s41423-022-00865-2

Ejemplares similares

CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
por: Bullock, Timothy N. J.
Publicado: (2021)

Correction: Vitetta, L.; et al. Adjuvant Probiotics and the Intestinal Microbiome: Enhancing Vaccines and Immunotherapy Outcomes. Vaccines 2017, 5, 50
por: Vitetta, Luis, et al.
Publicado: (2018)

Author Correction: Downregulation of CD40L–CD40 attenuates seizure susceptibility and severity of seizures
por: Pototskiy, Esther, et al.
Publicado: (2021)

Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer
por: Mohsen, Mona O., et al.
Publicado: (2019)

Author Correction: CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions
por: Liu, Pu-Ste, et al.
Publicado: (2023)

Correction: CD40 Activation Rescues Antiviral CD8(+) T Cells from PD-1-Mediated Exhaustion
por: Isogawa, Masanori, et al.
Publicado: (2016)

Correction: CD40 Activation Rescues Antiviral CD8(+) T Cells from PD-1-Mediated Exhaustion
por: Isogawa, Masanori, et al.
Publicado: (2017)

Correction: CD40: Novel Association with Crohn's Disease and Replication in Multiple Sclerosis Susceptibility
por: Blanco-Kelly, Fiona, et al.
Publicado: (2010)

Correction: Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Publicado: (2023)

The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40
por: Khong, Andrea, et al.
Publicado: (2014)

Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
por: Coccia, Margherita, et al.
Publicado: (2018)

Correction: Phytol-based novel adjuvants in vaccine formulation: 1. assessment of safety and efficacy during stimulation of humoral and cell-mediated immune responses
por: Lim, So-Yon, et al.
Publicado: (2007)

Author Correction: Localized nuclear reaction breaks boron drug capsules loaded with immune adjuvants for cancer immunotherapy
por: Shi, Yaxin, et al.
Publicado: (2023)

Correction: DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
Publicado: (2022)

Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines
por: Ceglia, Valentina, et al.
Publicado: (2022)

Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
por: Segura-Collar, Berta, et al.
Publicado: (2023)

Correction to: Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used
por: Fear, Vanessa S., et al.
Publicado: (2021)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Publicado: (2021)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
Publicado: (2023)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
Publicado: (2021)

Correction: CD40 Gene Silencing Reduces the Progression of Experimental Lupus Nephritis Modulating Local Milieu and Systemic Mechanisms
por: Ripoll, Èlia, et al.
Publicado: (2013)

Correction: Characterization of the Structure and Immunostimulatory Activity of a Vaccine Adjuvant, De-O-Acylated Lipooligosaccharide
Publicado: (2014)

P02-06. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine
por: Liu, J, et al.
Publicado: (2009)

Correction: CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
Publicado: (2022)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma
por: Gamache, Awndre, et al.
Publicado: (2023)

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
por: Salomon, Ran, et al.
Publicado: (2022)

Correction: CD40L promotes development of acute aortic dissection via induction of inflammation and impairment of endothelial cell function
por: Han, Lu, et al.
Publicado: (2018)

Correction: Immunotheranostic microbubbles (iMBs) - a modular platform for dendritic cell vaccine delivery applied to breast cancer immunotherapy
por: Jugniot, Natacha, et al.
Publicado: (2022)

Correction to: Immunology of allergen immunotherapy
Publicado: (2023)

Correction: Splenomegaly in Colon Cancer During Adjuvant Oxaliplatin-based Chemotherapy
por: Eren, Tulay, et al.
Publicado: (2020)

Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2008)

Correction to: Immunotherapy in prostate cancer: new horizon of hurdles and hopes
por: Tsaur, Igor, et al.
Publicado: (2021)

Correction to: Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
por: Kawakubo, Kazumichi, et al.
Publicado: (2022)

Author Correction: Dithranol as novel co-adjuvant for non-invasive dermal vaccination
por: Sohl, Julian, et al.
Publicado: (2023)

Correction: How Does Cross-Reactive Stimulation Affect the Longevity of CD8+ T Cell Memory?
por: Ganusov, Vitaly V, et al.
Publicado: (2006)

Correction to: Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains
por: Padron-Regalado, Eriko
Publicado: (2020)

Correction to: Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients
por: Marken, John, et al.
Publicado: (2021)

Correction to Lancet Respir Med 2021; 9: 1130–40
Publicado: (2021)

Correction: Correction: Meta-analysis of postoperative adjuvant therapy for small bowel adenocarcinoma
por: Ye, Xiaojian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kcgnm91tsd6ovjco7r88qkurjl